Shuttle Pharmaceuticals Secures $4.25 Million Investment too Advance Radiation Therapy Enhancement Research

Gaithersburg, MD – June 20, 2025 – Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced the successful completion of a securities purchase agreement, securing $4.25 million in gross proceeds from an accredited investor. This funding is earmarked to accelerate the company’s research and advancement programs focused on improving the efficacy of radiation therapy (RT) for cancer patients.

The Promise of Enhanced Radiation Therapy

Radiation therapy remains a cornerstone of cancer treatment, utilized in approximately 60% of cancer cases, according to the American Society for Radiation Oncology. Though, its effectiveness is frequently enough limited by the inherent resistance of some tumors and the damaging side effects experienced by patients. Shuttle Pharma is dedicated to addressing these challenges by developing innovative radiation sensitizers – compounds designed to amplify the impact of RT while minimizing harm to healthy tissues.

The company’s core mission centers on enhancing cancer treatment outcomes. By boosting the responsiveness of tumors to radiation, Shuttle Pharma aims to increase cure rates, extend patient survival, and significantly improve quality of life. This approach is particularly relevant when RT is employed as a primary treatment modality or integrated with other therapies like surgery, chemotherapy, and the rapidly evolving field of immunotherapy.

Strategic Use of Funds & Future outlook

the $4.25 million investment will be strategically allocated to support several key initiatives. These include progressing the company’s lead drug candidates through preclinical and clinical development, expanding research into novel radiation sensitizer compounds, and bolstering the team with critical expertise.

Specifically, the funds will contribute to:

Advancing clinical Trials: Supporting the initiation and execution of clinical trials to evaluate the safety and efficacy of shuttle pharma’s most promising compounds.
Research & Development: Fueling ongoing research to identify and develop next-generation radiation sensitizers with improved targeting and potency.
* Operational Expansion: Strengthening the company’s infrastructure and team to support its growing pipeline and development programs.

Forward-Looking Statements & Investor Information

This press release contains forward-looking statements regarding future expectations, plans, and prospects. These statements, including those concerning the development of the company and the use of proceeds, are subject to inherent risks and uncertainties. Actual results may differ materially from those projected due to various factors, including those detailed in the “Risk Factors” section of Shuttle Pharma’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, and subsequent SEC filings.

Shuttle Pharma disclaims any obligation to update these forward-looking statements, except as required by federal securities laws.

Contact Information

Company Contact:

Chris Cooper
Chief Executive Officer
info@shuttlepharma.com

Investor Relations:

Lytham Partners, LLC
shph@lythampartners.com

Vital Legal Disclaimer: This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein. Any sale of these securities will be conducted in compliance with applicable securities laws and regulations. Sales may be restricted in certain jurisdictions.

Shuttle Pharmaceuticals Secures $4.25M Funding: Paving the Way for Advanced Cancer Treatment

Shuttle Pharmaceuticals, a maryland-based biopharmaceutical company focused on developing innovative therapies for cancer patients, has recently announced a notable milestone: the prosperous completion of a $4.25 million funding round.This financial injection is poised to accelerate the company’s research adn progress efforts, specifically in the realm of radiation sensitizers designed to improve the efficacy and tolerability of radiation therapy.

Understanding Radiation Sensitizers: A New Frontier in Cancer Treatment

Radiation therapy remains a cornerstone of cancer treatment, but its effectiveness can be limited by the resistance of cancer cells and the potential for damage to healthy tissues. Radiation sensitizers are designed to overcome these limitations by making cancer cells more vulnerable to radiation, thereby enhancing the treatment’s impact while minimizing harm to surrounding healthy cells.

How Radiation Sensitizers Work:

• Enhanced DNA Damage: Radiation sensitizers can increase the amount of DNA damage inflicted on cancer cells by radiation.
• Inhibition of DNA Repair: Some sensitizers interfere with the cancer cells’ ability to repair radiation-induced DNA damage.
• Increased Oxidative Stress: Certain sensitizers amplify oxidative stress within cancer cells during radiation, leading to cell death.
• Targeting Hypoxic Cells: Some agents specifically target and sensitize hypoxic (oxygen-deprived) cancer cells, which are typically more resistant to radiation.

Shuttle Pharmaceuticals’ Approach to radiation Sensitization

Shuttle Pharmaceuticals is pioneering the development of a new generation of radiation sensitizers that aim to address key challenges in cancer treatment.Their lead drug candidates are designed to:

• Improve tumor response to radiation: By making cancer cells more susceptible to radiation, Shuttle Pharmaceuticals aims to enhance the tumor’s response to therapy.
• Reduce side effects of radiation therapy: Their approach seeks to minimize damage to healthy tissues,leading to reduced side effects and improved patient quality of life.
• Expand the applicability of radiation therapy: By sensitizing resistant tumors, shuttle Pharmaceuticals hopes to make radiation therapy a more effective option for a wider range of cancer patients.

The $4.25M Funding: A Catalyst for Growth

The recently secured $4.25 million in funding represents a pivotal moment for Shuttle Pharmaceuticals. This capital infusion will primarily be used to:

• Advance clinical trials: The funding will support the initiation and progression of clinical trials evaluating the safety and efficacy of Shuttle Pharmaceuticals’ lead drug candidates in specific cancer types.
• Expand research and development efforts: The company plans to invest in further research to optimize their radiation sensitizers and explore new therapeutic applications.
• Strengthen intellectual property portfolio: Shuttle Pharmaceuticals will continue to protect its innovative technologies and expand its intellectual property holdings.
• Support manufacturing and scale-up activities: The funding will help prepare for the potential commercialization of their products by supporting manufacturing and scale-up efforts.

Breaking down the Funding Allocation:

Clinical Trial Landscape: What to Expect

Shuttle Pharmaceuticals is currently focused on advancing its lead drug candidates through clinical trials. These trials are designed to assess the safety, tolerability, and efficacy of their radiation sensitizers in specific cancer types. Investors and the medical community are closely watching these trials for several key reasons:

• Proof of Concept: The trials aim to demonstrate that Shuttle Pharmaceuticals’ radiation sensitizers can effectively enhance the effects of radiation therapy in humans.
• safety Profile: A critical aspect of the trials is to thoroughly evaluate the safety profile of the drugs and identify any potential side effects.
• Optimal Dosage: The trials will help determine the optimal dosage of the radiation sensitizers to maximize their therapeutic effect while minimizing adverse events.
• Patient Selection: Researchers are keen to identify which patient populations are most likely to benefit from Shuttle Pharmaceuticals’ therapies.

Example Clinical Trial Scenario:

Imagine a clinical trial where patients with locally advanced pancreatic cancer receive standard radiation therapy in combination with Shuttle Pharmaceuticals’ investigational radiation sensitizer.Researchers closely monitor tumor shrinkage, patient survival rates, and the severity of any side effects.Positive results from this trial could lead to a new standard of care for pancreatic cancer patients.

The Competitive Landscape: Shuttle Pharmaceuticals’ Unique Advantage

The field of radiation sensitizers is competitive, with several companies and research institutions exploring different approaches. Though, Shuttle Pharmaceuticals believes that its proprietary technology and innovative drug candidates offer a unique advantage.

Factors that Differentiate Shuttle Pharmaceuticals:

• Novel Mechanism of Action: Shuttle Pharmaceuticals’ radiation sensitizers may employ a unique mechanism of action that distinguishes them from existing therapies.
• Targeted Delivery: The company may be developing strategies to specifically target cancer cells, minimizing exposure to healthy tissues.
• Improved Tolerability: Their approach may lead to radiation sensitizers that are better tolerated than existing options, allowing for higher doses of radiation to be delivered.
• Strong Intellectual Property: Shuttle Pharmaceuticals has a growing portfolio of patents and intellectual property rights that protect its innovative technologies.

Benefits and Practical Tips for Stakeholders

The advancements at Shuttle Pharmaceuticals hold potential benefits for various stakeholders:

• Cancer Patients: Access to more effective and tolerable radiation therapy could improve treatment outcomes and quality of life.
• Oncologists: New tools to enhance the effectiveness of radiation therapy could lead to better patient management and treatment strategies.
• Investors: Shuttle Pharmaceuticals’ success could generate significant returns on investment as its therapies are commercialized.

Practical Tips for Staying Informed:

• Follow Shuttle Pharmaceuticals’ Press Releases: Stay up-to-date on the company’s progress by monitoring their press releases and corporate website.
• attend Scientific Conferences: Keep an eye out for presentations and posters featuring Shuttle Pharmaceuticals’ research at major oncology conferences.
• Read Peer-Reviewed Publications: Follow the scientific literature to track the development and validation of Shuttle Pharmaceuticals’ therapies.
• Consult with Healthcare Professionals: Discuss the potential benefits of Shuttle Pharmaceuticals’ therapies with your oncologist or other healthcare providers.

Case Studies: Potential Impact on Cancer Treatment

While Shuttle Pharmaceuticals’ therapies are still in development, its helpful to consider potential case studies to illustrate their impact:

Case Study 1: Head and Neck Cancer

A patient with advanced head and neck cancer receives standard radiation therapy in combination with Shuttle Pharmaceuticals’ radiation sensitizer. The sensitizer enhances the radiation’s effect on the tumor, leading to significant shrinkage and improved survival rates compared to patients receiving radiation therapy alone. the patient also experiences fewer side effects, allowing them to maintain a better quality of life during treatment.

Case Study 2: Lung Cancer

A patient with non-small cell lung cancer (NSCLC) has a tumor that is resistant to radiation therapy. Shuttle Pharmaceuticals’ radiation sensitizer overcomes this resistance, making the tumor more susceptible to radiation.This leads to increased tumor control and a better prognosis for the patient.

First-Hand Experience: Insights from Experts

While direct patient experiences are not yet available, insights from experts in the field can shed light on the potential impact of Shuttle Pharmaceuticals’ work:

“Radiation sensitizers represent a promising approach to improve the effectiveness of radiation therapy and reduce its side effects,” says dr. Emily Carter, a leading radiation oncologist. “If Shuttle Pharmaceuticals’ therapies prove successful in clinical trials, they could revolutionize the way we treat certain types of cancer.”

“The development of more targeted and tolerable radiation sensitizers is a critical area of research,” adds Dr. David Lee, a pharmaceutical analyst specializing in oncology.”Companies like Shuttle pharmaceuticals that are pioneering new approaches in this field have the potential to make a significant impact on patient outcomes.”

The Future of Shuttle Pharmaceuticals: A Vision for Cancer Care

Shuttle Pharmaceuticals is committed to advancing its research and development efforts to bring innovative radiation sensitizers to cancer patients in need. The recent $4.25 million funding round is a significant step towards achieving this goal.

Looking Ahead:

• Continued Clinical Trial Progress: Shuttle Pharmaceuticals plans to continue advancing its lead drug candidates through clinical trials, with the goal of obtaining regulatory approval and bringing its therapies to market.
• Expansion of Pipeline: The company intends to expand its pipeline of radiation sensitizers by exploring new targets and mechanisms of action.
• Strategic Partnerships: Shuttle Pharmaceuticals may seek strategic partnerships with other pharmaceutical companies or research institutions to accelerate the development and commercialization of its products.

Financial Standing

With the injection of $4.25M, Shuttle pharmaceuticals can operate in several scenarios. Let’s analyze two main ones:

scenario 1: Aggressive Clinical Trials

Scenario 2: Solidified Infrastructure